<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774280</url>
  </required_header>
  <id_info>
    <org_study_id>C-005</org_study_id>
    <nct_id>NCT00774280</nct_id>
  </id_info>
  <brief_title>Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen</brief_title>
  <acronym>BuCyvsBUFlu</acronym>
  <official_title>Randomized Comparison of Once-daily Intravenous Busulfan Plus Cyclophosphamide Versus Fludarabine as a Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation in Leukemia and Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cooperative Study Group A for Hematology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cooperative Study Group A for Hematology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. At the same time of registration, patients will be randomized to one of the two&#xD;
           conditioning therapy groups; Arm I (intravenous busulfan plus cyclophosphamide; BuCy) or&#xD;
           Arm II (intravenous busulfan plus fludarabine; BuFlu).&#xD;
&#xD;
        2. Randomization will be a stratified permuted-block design. 2.1The patients will be&#xD;
           stratified into standard risk vs. high risk group, and related vs. unrelated donor.&#xD;
           Standard risk group will be defined as follows: patients with acute leukemia in first&#xD;
           remission, CML in chronic phase, and MDS (RA or RARS categories). High risk group will&#xD;
           be defined as follows: patients with acute leukemia in relapse or in second or&#xD;
           subsequent remission, CML in accelerated or blastic phase, and MDS (CMMoL or RAEB&#xD;
           categories).&#xD;
&#xD;
      2.2.Pre-assigned block size is 8.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. TREATMENT PLAN&#xD;
&#xD;
             -  The patients will be admitted to laminar air flow room.&#xD;
&#xD;
             -  The patients will have triple lumen Hickman central venous catheter (CVC) placed.&#xD;
                Vancomycin 1 gm IV immediately prior to CVC placement and 1 gm q 12 hours for 3&#xD;
                doses. Chest X-ray should be taken after CVC placement to confirm the location of&#xD;
                CVC and absence of pneumothorax.&#xD;
&#xD;
             -  Lumbar puncture will be done and intrathecal preservative free methotrexate 10 ㎎/㎡&#xD;
                (not to exceed 12 ㎎ total) will be given. Folinic acid 15 ㎎ will be given po or IV&#xD;
                24 hours after intrathecal methotrexate and q 6 hours for a total of 4 doses.&#xD;
&#xD;
             -  Menstruating women will be given norethindrone (Norlutate) 10 ㎎ po daily.&#xD;
&#xD;
        2. The preparatory regimen is as follows:&#xD;
&#xD;
             -  Conditioning therapy will start on day -7 in patients who are randomized to receive&#xD;
                intravenous busulfan (Busulfex®; Orphan Medical, Minnetonka, MN) plus&#xD;
                cyclophosphamide. Busulfex 3.2 ㎎/㎏ will be administered once daily for 4 days (days&#xD;
                -7 to -4) followed by cyclophosphamide 60 ㎎/㎏ in D5W 200 ㎖ i.v. over 1-2 hours on&#xD;
                days -3 and -2. Busulfex will be diluted in normal saline 500 ㎖ and infused over 3&#xD;
                hours by pump through a central venous catheter The doses of Busulfex and&#xD;
                cyclophosphamide will be calculated using following guideline: 1) if actual body&#xD;
                weight (ABW) of the patient is less or equal to ideal body weight (IBW), ABW will&#xD;
                be used. 2) if ABW is greater than IBW but by less than 20%, then IBW will be used.&#xD;
                3) if ABW is greater than IBW by more or equal to 20 %, then the dose will be based&#xD;
                on; IBW + 25 % (ABW-IBW). IBW is calculated as follows: 50 ㎏ + 2.3 ㎏ (Height in&#xD;
                inch - 60) in male, and 45.5 ㎏ +2.3 ㎏ (Height in inch -60) (1 inch= 2.54 ㎝).&#xD;
&#xD;
             -  Conditioning therapy will start on day -7 in patients who are randomized to receive&#xD;
                Busulfex plus fludarabine (Fludara®, Schering AG, Berlin, Germany). Busulfex 3.2&#xD;
                ㎎/㎏ will be administered once daily for 4 days (days -7 to -4) and fludarabine 30&#xD;
                ㎎/㎡ will be infused intravenously over 30 minutes in D5W 100 ㎖ for 5 consecutive&#xD;
                days (days -6 to -2). The dose of Busulfex will be calculated using above-mentioned&#xD;
                guideline (see 5.5.1). The dose of fludarabine will be calculated using ABW.&#xD;
&#xD;
        3. GVHD prophylaxis&#xD;
&#xD;
             -  All patients will receive cyclosporine 1.5 ㎎/㎏ in NS 100 ㎖ i.v. over 2-4 hours q 12&#xD;
                hrs (dose of cyclosporine rounded to nearest 5 ㎎) starting day -1 at 9 a.m.&#xD;
                Cyclosporine dose will be adjusted to provide appropriate level and according to&#xD;
                the change of renal function (see Appendix II).&#xD;
&#xD;
             -  When the patients can tolerate oral medications, cyclosporine can be given p.o. 3&#xD;
                ㎎/㎏ (or two times the i.v. dose) q 12 hrs.&#xD;
&#xD;
             -  Cyclosporine dose will be decreased by 10 % every month starting day 60 of BMT&#xD;
                provided that there is no clinical evidence of GVHD.&#xD;
&#xD;
             -  In addition to cyclosporine, methotrexate 15 ㎎/㎡ will be given intravenously on day&#xD;
                1 and 10 ㎎/㎡ on days 3, 6, and 11. The dose of methotrexate will be decreased or&#xD;
                omitted according to the guideline provided in Appendix III.&#xD;
&#xD;
             -  Methotrexate will not be given to patients with acute leukemia or MDS who will&#xD;
                receive hematopoietic cell graft from an HLA-matched sibling donor&#xD;
&#xD;
        4. Bone marrow cell infusion&#xD;
&#xD;
             -  For ABO matched or minor mismatched transplantation, premedication with Avil 45.5mg&#xD;
                I.v. push and tylenol 600 ㎎ p.o. will be given. Stem cell will be infused over 1-2&#xD;
                hrs.&#xD;
&#xD;
             -  For major ABO mismatched transplantation, premedication with Avil 45.5 ㎎ i.v. push,&#xD;
                tylenol 600 ㎎ p.o., 10 % mannitol 100 g i.v. over 4 hrs will be started 30 min&#xD;
                before stem cell infusion, and hydrocortisone 250 ㎎ i.v. will be given immediately&#xD;
                before and 30 min of stem cell infusion.&#xD;
&#xD;
        5. Supportive cares.&#xD;
&#xD;
             -  Dilantin 15 ㎎/㎏ (ABW) in NS 200 ㎖ i.v. over 1 hour for loading on day -8, then 200&#xD;
                ㎎ p.o. bid through day -5. Dilantin dose should be adjusted to provide therapeutic&#xD;
                level.&#xD;
&#xD;
             -  Allopurinol 300 ㎎/day p.o. qd day -8 to -2.&#xD;
&#xD;
             -  Nystatin powder to groin, axilla, and perianal area bid from day -8 until absolute&#xD;
                neutrophil count (ANC) &gt; 3,000/㎕.&#xD;
&#xD;
             -  Sodium bicarbonate/saline mouthwash qid until mucositis is resolved.&#xD;
&#xD;
             -  Fluconazole 100 ㎎/day p.o. qd until ANC &gt; 3,000/㎕.&#xD;
&#xD;
             -  Ciprofloxacin 500 ㎎ p.o. bid (for selective bowel decontamination) until ANC &gt;&#xD;
                3,000/㎕. With the first fever spike, ciprofloxacin will be discontinued and broad&#xD;
                spectrum antibiotics will be begun.&#xD;
&#xD;
             -  Hydration will be done with 0.9 % NS at 100 ㎖/hour while the patients are receiving&#xD;
                busulfan.&#xD;
&#xD;
             -  IV Immunoglobulin 500 ㎎/㎏ (ABW) i.v. over 6 hours every other week starting day -7&#xD;
                until day 120, then every month until day 180.&#xD;
&#xD;
             -  Prophylaxis against Herpes simplex virus will include acyclovir 250 ㎎/㎡ in D5W 100&#xD;
                ㎖ i.v. q 8 hours starting at day -7. When the patient can tolerate oral medication,&#xD;
                acyclovir will be given 200 ㎎ p.o. tid until day 180.&#xD;
&#xD;
             -  Prophylaxis against Pneumocystis carinii will include Bactrim SS 2 tablets p.o. bid&#xD;
                with folinic acid 7.5 ㎎ p.o. bid, 2 days weekly, starting after engraftment through&#xD;
                day 360.&#xD;
&#xD;
             -  Amoxacillin 250 ㎎ p.o. bid starting at day 70 through day 360.&#xD;
&#xD;
             -  G-CSF administration.&#xD;
&#xD;
             -  Starting day 5, G-CSF 300 ㎍ in 100 ㎖ of D5W will be given i.v. over 3 hours daily&#xD;
                until ANC &gt; 3,000/㎕.&#xD;
&#xD;
             -  If ANC drops below 1,000/㎕, G-CSF administration will resume and continue until ANC&#xD;
                &gt; 3,000/㎕.&#xD;
&#xD;
        6. In patients with acute leukemia or CML in blastic crisis, intrathecal methotrexate&#xD;
           administration will be resumed after the patient recovered platelet count to over&#xD;
           50,000/㎕. Methotrexate 10 ㎎/㎡ (not to exceed 12 ㎎ total) will be given intrathecally&#xD;
           once every 2 weeks for three times (total four doses including one given before&#xD;
           preparatory regimen). Folinic acid 15 ㎎ will be given p.o. or i.v. 24 hours after&#xD;
           intrathecal methotrexate and q 6 hours for a total of 4 doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2002</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>related toxicities of two different conditioning regimens, intravenous once-daily busulfan plus cyclophosphamide (BuCy) vs. fludarabine (BuFlu) for allogeneic hematopoietic cell transplantation (HCT) in leukemia and myelodysplastic syndrome</measure>
    <time_frame>8years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>ArmI(BuCy)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Intravenous busulfan (Busulfex®; Orphan Medical, Minnetonka, MN) 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4&#xD;
Cyclophosphamide 60 ㎎/㎏ in D5W 200 ㎖ i.v. over 1-2 hours on days -3 and -2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (BuFlu)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Intravenous busulfan 3.2 ㎎/㎏ in normal saline 500 ㎖ i.v. over 3 hours on days -7 to -4.&#xD;
Fludarabine (Fludara®, Schering AG, Berlin, Germany) 30 ㎎/㎡ i.v. over 30 minutes in D5W 100 ㎖ on days -6 to -2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BuCy vs BuFlu</intervention_name>
    <description>Arm 1:BuCy Arm 2:BuFlu</description>
    <arm_group_label>Arm II (BuFlu)</arm_group_label>
    <arm_group_label>ArmI(BuCy)</arm_group_label>
    <other_name>busulfan plus cyclophosphamide versus fludarabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with acute leukemia, chronic myelogenous leukemia, myelodysplastic syndrome,&#xD;
             and other hematologic malignancies.&#xD;
&#xD;
          -  Patients should have an HLA-identical or one-locus mismatched sibling, family or&#xD;
             unrelated donor.&#xD;
&#xD;
          -  Patients should be 15 years of age or older, but younger than 70 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients have major illness or organ failure.&#xD;
&#xD;
          -  Patients have a psychiatric disorder or mental deficiency severe as to make compliance&#xD;
             with the treatment unlike, and making informed consent impossible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Je-Hwan Lee, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.google.co.kr</url>
    <description>BuCy vs BuFlu</description>
  </link>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <last_update_submitted>February 10, 2011</last_update_submitted>
  <last_update_submitted_qc>February 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 14, 2011</last_update_posted>
  <responsible_party>
    <name_title>Je-Hwan Lee</name_title>
    <organization>Asan Medical Center</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

